Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Ninth Annual World Conference of the Human Proteome Organization -- Agilent Technologies Inc. (NYSE:A) today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that Health Canada has issued a medical device license for its automated IgX PLEX Celiac(TM) microarray test kit that runs on the Company's automated SQiDworks(TM) platform. The license allows the Company to market and sell the IgX PLEX Celiac product in Canada.

21 Sep 2010

APAF selects AB SCIEX TripleTOF 5600 System to help advance proteomics research

AB SCIEX, a global leader in life science analytical technologies, today announced that the Australian Proteome Analysis Facility has chosen the AB SCIEX TripleTOF 5600 System to help advance proteomics research by significantly expanding proteome coverage. The TripleTOF 5600 System is the life science industry's fastest and most sensitive high-resolution mass spectrometer for high-performance qualitative and quantitative analysis.

20 Sep 2010

Immunotherapy accepted for coverage in MEDLINE®

Future Medicine Ltd announced today that its journal Immunotherapy (ISSN 1750-743X) has been selected for coverage in MEDLINE®. Maintained by the U.S. National Library of Medicine, MEDLINE® (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in life sciences.

19 Sep 2010

Blood test developed for non-alcoholic fatty liver disease diagnosis

Scientists at the Basque Center for Cooperative Research in Biosciences (CIC bioGUNE) and OWL Genomics Ltd. (Bilbao, Spain), in collaboration with researchers at the INSERM and University Hospitals (APHP Pitié Salpêtrière Hospital, Pierre & Marie Curie University Paris and Centre Hospitalier Universitaire Nice, University of Nice-Sophia-Antipolis, Nice, France), Vanderbilt University (Nashville, US), the University of Southern California (Los Angeles, US), Clinic Hospital and IDIBAPS (Barcelona, Spain) and the Alcalá de Henares University (Alcalá de Henares, Spain) have used metabolomics technology to develop a blood test for non-alcoholic fatty liver disease (NAFLD) diagnosis.

19 Sep 2010

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Scott & White Healthcare in Round Rock, Texas is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

17 Sep 2010

Metabolism imbalance increases asthma risk in children: Research

Even children of a healthy weight who have an imbalanced metabolism due to poor diet or exercise may be at increased risk of asthma, according to new research, which challenges the widespread assumption that obesity itself is a risk factor for asthma.

17 Sep 2010

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

Roche Diagnostics announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes.

From Roche Sequencing and Life Science 17 Sep 2010

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

16 Sep 2010

Researchers develop ChIP Enrichment Analysis to identify drug targets, biomarkers

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers.

16 Sep 2010

Diaceutics, London Genetics partner to develop software decision tools for biomarker research

Diaceutics Limited and London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, today announce a strategic partnership to develop software decision tools that will provide biopharmaceutical companies with rapid and extensive access to the world's leading academic biomarker research groups.

15 Sep 2010

Norgen Biotek launches three novel kits for urine sampling

Norgen Biotek Corp, a privately held Canadian biotechnology company focusing principally on advancing a powerful proprietary technology for application in sample preparation for nucleic acid (DNA, RNA and microRNA) and protein purification, today announced the expansion of its basket of urine-based sample preparation products by launching 3 new urine concentration, preservation and isolation kits.

15 Sep 2010

Compandia is now CompanDX

Compandia has announced a name change to CompanDX. The company is a biomarker discovery company providing services to the Pharma and Biotech sectors but increasingly, as a result of in-house R&D, is identifying biomarkers that may lead to new diagnostic services and products of its own. Andy Sutton CEO of CompanDX explained "we have grown the service side of the business over the last 9 months and are delivering biomarker discovery services to large pharma, small biotech and diagnostic companies.

15 Sep 2010

20-20 Gene Systems launches L-IHC staining for biomarker identification in tumors

20/20 GeneSystems, Inc. announced today at ADAPT 2010, an industry meeting focusing on advancing personalized medicine, the commercial launch of their patented technology for biomarker identification in tumors and other tissue samples. 20/20 is currently offering the technology to industry and academic researchers under service contracts.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

Metabolon receives patent for metabolic age analysis

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled "Biomarkers Related to Metabolic Age and Methods Using the Same". The USPTO awarded the patent to Metabolon on August 24, 2010. This is the 12th patent issued to Metabolon.

14 Sep 2010

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Swimming in indoor chlorinated pools may induce genotoxicity (DNA damage that may lead to cancer) as well as respiratory effects, but the positive health effects of swimming can be maintained by reducing pool levels of the chemicals behind these potential health risks, according to a new study published in a set of three articles online September 12 ahead of print in the peer-reviewed journal Environmental Health Perspectives (EHP).

13 Sep 2010